Overview

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Status:
Recruiting
Trial end date:
2021-11-20
Target enrollment:
Participant gender:
Summary
The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).
Phase:
Phase 3
Details
Lead Sponsor:
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Treatments:
Docetaxel
Pertuzumab
Trastuzumab